Investigational drug · Phase 2
Tenalisib
Also called: RP6530
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Triple Negative Breast Cancer (TNBC).
Phase 2Last checked: Nov 19, 2026Latest source record: Dec 2, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
11
Any phase or sponsor naming "Tenalisib"
First trial start
2024
Mar 4, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Tenalisib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Triple Negative Breast Cancer (TNBC)
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Tenalisib" as an intervention, largest first.
Rhizen Pharmaceuticals SAIndustry
NCT02567656 · 58 participants · Start Sep 2015 · Primary completion Mar 2018
Drug: RP6530 · For: Lymphoma, T-Cell, Peripheral; Lymphoma, T-Cell, Cutaneous
Sites: Duarte, California; Orange, California; Aurora, Colorado · 8 sites in all
- Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)Recruiting
Rhizen Pharmaceuticals SAIndustry
NCT06189209 · 40 participants (planned) · Start Mar 4, 2024 · Primary completion Dec 31, 2026
Drug: Tenalisib · For: Triple Negative Breast Cancer (TNBC)
Sites: Vijayawada, India; Bangalore, India; Mumbai, India · 9 sites in all
Rhizen Pharmaceuticals SAIndustry
NCT05021900 · 40 participants · Start Oct 13, 2021 · Primary completion Mar 31, 2023
Drug: Tenalisib 800mg; Tenalisib 1200mg · For: Locally Advanced Breast Cancer; Metastatic Breast Cancer
Sites: Batumi, Georgia; Tbilisi, Georgia · 3 sites in all
- Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological MalignanciesCompleted
Rhizen Pharmaceuticals SAIndustry
NCT02017613 · 35 participants · Start Nov 2013 · Primary completion May 2016
Drug: RP6530 · For: Lymphoma, B-Cell; T-Cell Lymphoma
Sites: Paris, France; Milan, Italy · 3 sites in all
Rhizen Pharmaceuticals SAIndustry
NCT03770000 · 33 participants · Start Mar 12, 2019 · Primary completion May 14, 2021
Drug: Tenalisib; Romidepsin · For: T Cell Lymphoma
Sites: Los Angeles, California; San Francisco, California; Aurora, Colorado · 15 sites in all
Rhizen Pharmaceuticals SAIndustry
NCT04204057 · 21 participants · Start Nov 28, 2019 · Primary completion Oct 2, 2020
Drug: Tenalisib · For: Leukemia, Lymphocytic, Chronic, B-Cell
Sites: Pleven, Bulgaria; Sofia, Bulgaria; Tbilisi, Georgia · 6 sites in all
Rhizen Pharmaceuticals SAIndustry
NCT03711578 · 20 participants · Start Nov 25, 2018 · Primary completion Jun 16, 2020
Drug: Tenalisib, · For: Non Hodgkin Lymphoma
Sites: Huntsville, Alabama; Denver, Colorado; Florida City, Florida · 12 sites in all
Rhizen Pharmaceuticals SAIndustry
NCT02690727 · 18 participants · Start Feb 2016 · Primary completion Mar 2016
Drug: RP6530 · For: Healthy
Sites: Québec, Canada
Rhizen Pharmaceuticals SAIndustry
NCT03711604 · 17 participants · Start Nov 28, 2018 · Primary completion Mar 25, 2023
Drug: Tenalisib · For: Hematological Malignancies
Sites: San Francisco, California; Denver, Colorado; Cleveland, Ohio · 7 sites in all
Rhizen Pharmaceuticals SAIndustry
NCT03471351 · 2 participants · Start Jul 18, 2018 · Primary completion Feb 13, 2019
Drug: Tenalisib; Pembrolizumab · For: Classical Hodgkin Lymphoma
Sites: Chicago, Illinois; Detroit, Michigan; Seattle, Washington
Newest research
PubMed records naming it or its code names, newest first.
- Osteosarcoma-on-a-chip model mimicking intra-tumoral heterogeneity to interrogate tumor-associated macrophage reprogramming for immunotherapeutics.
Jaiswal C, Sugihara S, Dey S, et al. · Biomaterials 2026
- Emerging Therapeutic Strategies in Cutaneous T-Cell Lymphoma: A Comprehensive Review of Clinical Trials.
Sacknovitz Y, Ma R, Bear CM, et al. · Am J Clin Dermatol 2026
- Management of Mycosis Fungoides and Sézary Syndrome With Oral Systemic Therapies.
Greenzaid JD, Thakker S, Ruley AJ, et al. · J Cutan Med Surg 2025
- Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study.
Iyer SP, Huen A, Ai WZ, et al. · Haematologica 2024
- Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory sézary syndrome.
Nguyen CN, Iyer SP, Duvic M, et al. · Invest New Drugs 2023
- Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma.
Huen A, Haverkos BM, Zain J, et al. · Cancers (Basel) 2020
Also in development for Triple Negative Breast Cancer (TNBC)
- B1962Phase 22 trials
Tasly Biopharmaceuticals Co., Ltd. · Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Cervical Cancers
- GTAEXS617REC-617Phase 21 trial
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. · Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC)
- IOV-5001Phase 21 trial
Iovance Biotherapeutics, Inc. · Advanced Solid Tumors, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.